The occurrence of the JAK2 V617F (Janus Kinase 2) mutation is notably high, up to 97% in individuals with PV and approximately 60% in those with ET and PMF, with no significant difference between prefibrotic and overt PMF [4,5,6,7]. The gene discussed is JAK2; the disease is essential thrombocythemia.